GILD - CIK 0000882095
The table below shows GILEAD SCIENCES, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B | $8.17B |
| Capital expenditure | $563.00M | $523.00M | $585.00M | $728.00M | $579.00M | $650.00M |
| Investing cash flow | -$4.79B | -$3.45B | -$2.27B | -$2.47B | -$3.13B | -$14.62B |
| Dividends paid | $4.00B | $3.92B | $3.81B | $3.71B | $3.60B |
GILEAD SCIENCES, INC. reported operating cash flow of $10.02B for fiscal year 2025. That is down 7.5% from $10.83B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $17.05B (FY 2016) to $10.02B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.45B |
| Stock buybacks | $1.92B | $1.15B | $1.00B | $1.40B | $546.00M | $1.58B |
| Financing cash flow | -$7.75B | -$3.43B | -$5.13B | -$6.47B | -$8.88B | $770.00M |